MEMO RE Covid-19 Federal Govt Regulatory Failures, Crimes and Attempts to Avoid Liability.docx


Executive Summaries of Exhibits/

    DOD BARDA OTA Contracts.docx
    Legal History of American Domestic Bioterrorism Program.docx
    Legal History of American Domestic Bioterrorism Program.pdf
    cGMP Noncompliance.docx


Supporting Documentation for Exhibits/

    cGMP noncompliance/
        Brandon Johnson supplement Coker v Austin.pdf
        M1 20 Nov 2020 FDA Query Res19.pdf

        Analysis of BNT162b2 Manufacture/
            22OC29_EMA-Analysis-of-BNT162b-Manufacture (1).pdf
            CCCA Presentation.pptx
            alexandra-latypova-expert-report-docx.pdf

        Batch variability analysis/
            Covid_vs_Flu_vax_v1.pdf
            Failure to Scale - Test the vials.pdf
            Hot Lot Update_Jul15 2022.pdf
            alexandra-latypova-expert-report-docx.pdf

            Technical appendix/
                LtL Variability Analysis.xlsx
                Mod_Lot_041L20A-allAE-allGeo-datevax.xlsx

                C19V Source data/
                    All C19 Manuf_LotN_US_AllAE.txt
                    All C19 Manuf_LotN_US_SAEonly.txt
                    All C19 manuf Foreign_All AE.txt
                    All C19 manuf Foreign_Deaths.txt
                    All C19 manuf Foreign_SAE.txt

                Flu source data/
                    FLU_INJECT_AllManuf_US.txt
                    FLU_INJECT_AllManuf_US_Deathonly.txt
                    FLU_INJECT_AllManuf_US_SAEOnly.txt

        EMA Leaked emails/
            EMA LEAKS/
                MLT rolling report on COVID-19 discussions.docx
                Nov 22.PNG
                Nov 23.png
                Nov11.PNG
                Nov12-II.PNG
                Nov12.PNG
                Nov16.PNG
                Nov19.PNG
                Nov20.PNG
                Nov23-II.PNG
                Nov23.PNG
                Nov24.PNG
                Nov25-II.PNG
                Nov25.PNG
                before Nov21.PNG

        Evidence of harm from countermeasures/
            Benzi+Cipelli+et+al.+proof+1.12.pdf
            EvidentiaryDocument_COVID19NationalLevelHarm_01122022.pdf
            M Palmer organ damage causality.pdf

        FDA audit forms 483/
            Rentschler Biopharma, Laupheim, Germany 2.15.22_483.pdf
            applied-KM-Catalent Indiana LLC_FEI 3005949964_483-09_01_2022_Redacted.pdf

        HRees Expert Report Supply Chain cGMP/
            Hedley Expert report_17122021.pdf

        Independent testing of vax vials/
            2021-Nov  Analyse 2_Neu.pdf
            26 groups imaging finding JVTPR.pdf
            Dr Schmidt-Kruger - Summary.docx
            Report on contaminants in Cov-Injections.pdf
            V1 working group vax vial analysis.pdf
            alignment biontech.xlsx

        Other Transaction Authority/
            2020.06.29 KEI Brief on OTA KEI-Briefing-OTA-29june2020.pdf

        Regulatory Review Documents/
            20201126_BNT162b2_EMAmeeting14.pptx
            COVID-19 mRNA Vaccine BioNTe24.docx

    Role of DOD and BARDA/
        2020.06.29 KEI Brief on OTA KEI-Briefing-OTA-29june2020.pdf
        FDA Briefing on Development of C-19 Vaccines.pdf
        Medical CBRN Defense Consortium_Pfizer and Novavax.pdf
        NIH-Moderna-Confidential-Agreements.pdf
        VRBPAC-10.22.20-Meeting-Presentation-COVID19-Vaccine-Development-NIH-Role.pdf
        VRBPAC-10.22.20-Meeting-Presentation-COVID19-Vaccine-Development-Portfolio.pdf
        signal-2022-11-16-07-58-29-843.mp4

        DOD-BARDA contracts for countermeasures/
            BARDA-ModernaTX-Contract-75A50120C00034-16Apr2020.pdf
            BARDA-Protein-Sciences-Corp-Contract-HHSO100201600005I-14Feb2020.pdf
            DOD-ATI-Contract-MCDC-Consortium-W15QKN1691002-P00085-8April2016.pdf
            DOD-ATI-Janssen-Contract-W15QKN1691002-P00081-Mod00001-21Sept2020.pdf
            DOD-ATI-Novavax-Contract-W15QKN1691002-25June2020.pdf
            DOD-ATI-Novavax-TDL-SOW-W15QKN1691002-6July2020-21Dec2020.pdf
            DOD-ATI-Novavax-Technical-Direction-Letter-W15QKN1691002-6July2020-HHSRR.pdf
            DOD-ATI-Pfizer-Technical-Direction-Letter-OTA-W15QKN-16-9-1002-21July2020.pdf
            DOD-GlaxoSmithKline-Contract-W15QKN20C0048-P00001-30July2020.pdf
            DOD-GlaxoSmithKline-Contract-W15QKN20C0048-P00002-16Sept2020.pdf
            DOD-Moderna-Contract-W911QY20C0100-9Aug2020-HHSFOIAReadingRoom.pdf
            DOD-Moderna-Contract-W911QY20C0100-P00007-15June2021.pdf
            DOD-Novavax-Contract-W911QY20C0077-P00001-4June2020.pdf
            DOD-Ology-Bioservices-Contract-W911QY2090003-21Feb2020.pdf
            DOD-Ology-OTA-W911QY2090003-21Feb2020.pdf
            DOD-Ology-OTA-W911QY2090003-Appendix A-4-20Mar2020.pdf
            DVA-Pfizer-Contract-V797D40269-P00376-1June2021.pdf
            DoD-Icon-OTA-Contract-W911QY2090007-27April2020.pdf
            DoD-Inovio-Contract-18June2020.pdf
            DoD-Inovio-OTA-22June2020.pdf
            DoD-Novavax-Statement-of-Work-W15QKN1691002.pdf
            DoD-Ology-Bioservices-Contract-W911QY20C0101-17Aug2020.pdf
            DoD-Pfizer-Contract-W15QKN21C0012-22Dec2020.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-15June2012.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-75A50120F33007-24May2020.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-75A50120F33007-P00001-24Aug2020.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-75A50120F33007-P00002-13May2020.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-75A50120F33007-P00003-7Oct2020.pdf
            HHS-BARDA-Emergent-SupplyOrder-Contract-HHSO100201200004I-24May2020.pdf
            HHS-BARDA-J&J-OTA-HHSO100201700018C-Amendment8-27March2020-FOIA.pdf
            HHS-BARDA-Moderna-Contract-75A50120C00034-16April2020-Version8Feb2021.pdf
            HHS-BARDA-Moderna-Contract-75A50120C00034-P00003-25July2020.pdf
            HHS-BARDA-TexasAM-Contract-HHSO100201200002I-75A50120F33002-23July2020.pdf
            HHS-BARDA-TexasAM-Contract-HHSO100201200002I-75A50120F33002-P00001-27Aug2020.pdf
            HHS-BARDA-TexasAM-Contract-HHSO100201200002I-75A50120F33002-P0002-9Oct2020.pdf
            HHS-BARDA-Vaxess-Technologies-Contract-75A50120C00160-6Aug2020.pdf
            HHS-Protein-Sciences-Sanofi-Contract-HHSO100201600005I-16Aug2016.pdf

            NIAID-Moderna/
                NIH-Moderna-Confidential-Agreements.pdf

Other affidavits/
    COVID Vaccine Death Excess and cGMP Fraud Summary of Evidence 10 19 2022.pdf

    Affidavit on 33 Pfizer batches/
        ALatypova Affidavit_GMP violations Pfizer batches_12-2022.pdf

        Attachments/
            20201126_BNT162b2_EMAmeeting14.pptx
            33-Pfizer batch-details tables.xlsx
            COVID-19 mRNA Vaccine BioNTe24.docx
            Latypova-Resume_102022.pdf
            M1 20 Nov 2020 FDA Query Res19.pdf

    Affidavits on non-clinical Pfizer and Moderna/
        ALatypova Moderna Affidavit 2 Dec 21 2022.docx
        Pfizer nonclinical review for DC$E website.pdf

    BARDA affidavit/
        BARDA subverts pharmacy regulations.docx

        Attachments - BARDA affidavit/
            signal-2022-11-16-07-58-29-843.mp4

    BARDA FOIA from CHD/
        2023-00322-FOIA-OS - responsive documents.pdf
        Final Response Letter - Full Release .pdf

    Pfizer batch variability witness statement/
        20201126_BNT162b2_EMAmeeting14.pdf
        Nov23.PNG
        Rapporteurs-Rolling-Review-Report-Quality-COVID-19-mRNA-Vaccine-BioNTec.doc
        Witness statement_VaxVariability_AlexandraLatypova.docx